Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Brought to you by:
ophthalmology
Brought to you by:
Biotech
Eye disease biotech launches with $100M, Roche rival in clinic
Ollin Biosciences has already enrolled 150 patients in a phase 1b trial pitting its bispecific antibody against Roche's blockbuster eye med Vabysmo.
Darren Incorvaia
Sep 17, 2025 6:30am
Iantrek sees $42M fundraising for alternative glaucoma surgery
Aug 20, 2025 11:50am
Opthea ramps up cuts to 85% of staff, including CEO
Aug 19, 2025 7:35am
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
Aug 19, 2025 7:18am
Boehringer pens $1B pact to reduce eye drug injections
Jul 28, 2025 8:48am
Okyo's eye drops reduce neuropathic eye pain in phase 2 win
Jul 16, 2025 11:57am
